Key Highlights

  • Q3 2026 net loss narrowed to $10.5 million, or $(0.15) per share, versus a net loss of $59.1 million, or $(0.85) per share, in Q3 2025.
  • Collaboration Revenue rose to $34.1 million in Q3 2026 from $11.7 million in Q3 2025, driven by recognition of remaining revenue upon termination of the Bayer collaboration.
  • The FDA granted Orphan Drug Designation to nuzefatide pevedotin for pancreatic cancer, providing development incentives including potential seven-year market exclusivity.
  • Cash and equivalents stood at $469.9 million as of September 30, 2026, supporting an expected runway into 2030.

Bicycle Therapeutics plc (NASDAQ:BCYC), a clinical-stage pharmaceutical company developing a proprietary class of constrained bicyclic peptide medicines, reported third-quarter 2026 results that show a marked narrowing of losses alongside advancing clinical and regulatory milestones. Net loss for the three months ended September 30, 2026, came in at $10.5 million, compared with a net loss of $59.1 million in the same period a year earlier, reflecting both higher collaboration revenue and meaningfully reduced operating expenses following workforce actions taken in 2025 and early 2026.

Revenue Surge Driven by Collaboration Termination Settlement

Collaboration revenue for the third quarter of 2026 totaled $34.1 million, compared with $11.7 million in the prior-year quarter. The increase was primarily attributable to the recognition of all remaining deferred revenue under the company's collaboration agreement with Bayer Consumer Care AG, which was terminated during the period. For the nine months ended September 30, 2026, collaboration revenue reached $35.6 million against $24.6 million in the same period of 2025. While the one-time nature of this revenue recognition inflates the quarterly figure, the underlying pipeline progress is what the company is pointing investors toward as a driver of future value.

Operating Expenses Decline Sharply Following Workforce Reductions

Research and development expenses fell to $33.4 million in Q3 2026 from $58.4 million in Q3 2025, a decrease of $25.0 million driven by lower clinical program costs for zelenectide, reduced personnel-related expenses and share-based compensation following headcount reductions announced in August 2025 and March 2026, and lower discovery and platform costs. General and administrative expenses similarly contracted to $14.1 million from $18.9 million in the year-ago period, again reflecting lower personnel costs resulting from the workforce reductions. For the nine months ended September 30, 2026, total operating expenses of $169.1 million compared with $247.0 million in the first nine months of 2025, representing a reduction of nearly $78 million — a significant shift in the company's cost structure.

Cash and cash equivalents were $469.9 million at September 30, 2026, down from $628.1 million at the end of 2025. The decrease reflects cash consumed by clinical program operations, though the company's runway is expected to extend into 2030 based on current plans.

FDA Designation and Pipeline Milestones Anchor Strategy

During the third quarter, the FDA granted Orphan Drug Designation to nuzefatide pevedotin — formerly BT5528, a Bicycle Drug Conjugate targeting EphA2 — for the treatment of pancreatic cancer. The designation applies to rare diseases affecting fewer than 200,000 patients in the United States and provides development incentives including tax credits on qualifying clinical trial costs, exemption from certain FDA user fees, and the potential for seven years of market exclusivity upon approval. Bicycle Therapeutics is actively enrolling patients in a Phase 2 trial evaluating nuzefatide in adults with recurrent pancreatic ductal adenocarcinoma, with further updates expected in 2027.

On the radioligand side, the company is advancing BT1702, a Bicycle Radioconjugate targeting MT1-MMP, with the first company-sponsored radioligand clinical trial expected to initiate in the second half of 2027. The company converted the Duravelo-2 trial for zelenectide pevedotin to a randomized Phase 2 trial in May 2026 and deprioritized the program for internal development, with survival data from the trial expected in the second half of 2027.

Balance Sheet and Cash Runway

Total Assets stood at $567.2 million at September 30, 2026, compared with $717.6 million at December 31, 2025, reflecting primarily the reduction in cash and cash equivalents. Total shareholders' Equity was $505.3 million. Working Capital of $493.1 million at quarter end compares to $625.9 million at year-end 2025. The company's financial position, supported by a cash runway into 2030, provides a meaningful buffer to advance its prioritized clinical programs through planned milestones without near-term financing pressure.

Bicycle Therapeutics enters the fourth quarter of 2026 with a narrower operating loss profile, a pipeline anchored by an FDA-designated program, and a cash position designed to support operations well into the next decade. The company's pivot away from zelenectide's internal development, combined with the termination of the Bayer collaboration, marks a reset that concentrates resources on nuzefatide in pancreatic cancer and the emerging radioligand platform built around BT1702. Whether these clinical programs generate the data needed for regulatory submissions in 2027 and beyond will define the company's trajectory.